Regulus Therapeutics (NASDAQ:RGLS) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.07, Fidelity Earnings reports. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%.
RGLS opened at $1.65 on Friday. Regulus Therapeutics has a 1-year low of $1.57 and a 1-year high of $17.28. The company has a market capitalization of $15.54 million, a PE ratio of -0.14 and a beta of 1.78.
A number of brokerages have issued reports on RGLS. Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday. Wedbush reissued a “hold” rating and issued a $2.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, October 9th. Finally, ValuEngine raised Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Nine research analysts have rated the stock with a hold rating, Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $1.42.
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.